Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 7 de 7
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Viruses ; 10(6)2018 05 28.
Article de Anglais | MEDLINE | ID: mdl-29843391

RÉSUMÉ

In this article we explain how current events in the field of phage therapy may positively influence its future development. We discuss the shift in position of the authorities, academia, media, non-governmental organizations, regulatory agencies, patients, and doctors which could enable further advances in the research and application of the therapy. In addition, we discuss methods to obtain optimal phage preparations and suggest the potential of novel applications of phage therapy extending beyond its anti-bacterial action.


Sujet(s)
Phagothérapie/tendances , Animaux , Bactéries/virologie , Bactériophages , Essais cliniques comme sujet , Humains , Immunomodulation , Souris , Prophages
2.
Cent Eur J Public Health ; 24(3): 188-192, 2016 09.
Article de Anglais | MEDLINE | ID: mdl-27755860

RÉSUMÉ

AIM: The aim of the study was to evaluate the hospitalization trends in children aged 0-6 suffering from bacterial pneumonia in the years 2007-2011 in Poland. METHODS: The data pertained to the hospitalized patients diagnosed with the diseases registered as J13-J15 according to ICD-10. RESULTS: In the years 2007-2011, the hospitalization rate increased from 16.3/10,000 to 44.1/10,000 for boys and from 13.8/10,000 to 33.0/10,000 for girls. The most frequently hospitalized children were between 1 and 2 years of age (90.6/10,000 for boys and 58.0/10,000 for girls in 2011). The average length of stay (LOS) of the investigated children fell from 10.1 days in 2007 to 8.2 days in 2011. The longest stays were recorded for the youngest children, under 2 years of age (from almost 11 days in 2007 to around 9 days in 2011). CONCLUSION: Bacterial pneumonia is a serious problem of public health and especially babies are at high risk of this disease. Given the effects of vaccinations against Streptococcus pneumoniae conducted all over the world and to a limited extend in Poland as well, further steps towards vaccinating children against pneumococci should be taken in Poland.


Sujet(s)
Enfant hospitalisé/statistiques et données numériques , Hospitalisation/tendances , Pneumopathie bactérienne/épidémiologie , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Nouveau-né , Durée du séjour/statistiques et données numériques , Mâle , Pologne/épidémiologie
3.
Pharm Res ; 32(7): 2173-9, 2015 Jul.
Article de Anglais | MEDLINE | ID: mdl-25585954

RÉSUMÉ

The worldwide antibiotic crisis has led to a renewed interest in phage therapy. Since time immemorial phages control bacterial populations on Earth. Potent lytic phages against bacterial pathogens can be isolated from the environment or selected from a collection in a matter of days. In addition, phages have the capacity to rapidly overcome bacterial resistances, which will inevitably emerge. To maximally exploit these advantage phages have over conventional drugs such as antibiotics, it is important that sustainable phage products are not submitted to the conventional long medicinal product development and licensing pathway. There is a need for an adapted framework, including realistic production and quality and safety requirements, that allows a timely supplying of phage therapy products for 'personalized therapy' or for public health or medical emergencies. This paper enumerates all phage therapy product related quality and safety risks known to the authors, as well as the tests that can be performed to minimize these risks, only to the extent needed to protect the patients and to allow and advance responsible phage therapy and research.


Sujet(s)
Infections bactériennes , Bactériophages/croissance et développement , Biothérapie , Multirésistance bactérienne aux médicaments , Infections bactériennes/microbiologie , Infections bactériennes/thérapie , Bactériophages/isolement et purification , Biothérapie/effets indésirables , Biothérapie/normes , Biothérapie/tendances , Humains
4.
Biomed Res Int ; 2014: 621316, 2014.
Article de Anglais | MEDLINE | ID: mdl-24868534

RÉSUMÉ

The excessive and improper use of antibiotics has led to an increasing incidence of bacterial resistance. In Europe the yearly number of infections caused by multidrug resistant bacteria is more than 400.000, each year resulting in 25.000 attributable deaths. Few new antibiotics are in the pipeline of the pharmaceutical industry. Early in the 20th century, bacteriophages were described as entities that can control bacterial populations. Although bacteriophage therapy was developed and practiced in Europe and the former Soviet republics, the use of bacteriophages in clinical setting was neglected in Western Europe since the introduction of traditional antibiotics. Given the worldwide antibiotic crisis there is now a growing interest in making bacteriophage therapy available for use in modern western medicine. Despite the growing interest, access to bacteriophage therapy remains highly problematic. In this paper, we argue that the current state of affairs is morally unacceptable and that all stakeholders (pharmaceutical industry, competent authorities, lawmakers, regulators, and politicians) have the moral duty and the shared responsibility towards making bacteriophage therapy urgently available for all patients in need.


Sujet(s)
Infections bactériennes/thérapie , Bactériophages/composition chimique , Résistance bactérienne aux médicaments , Antibactériens/usage thérapeutique , Bactéries , Infections bactériennes/traitement médicamenteux , Biothérapie/tendances , Industrie pharmaceutique/tendances , Déontologie médicale , Europe , Humains , Sens moral
5.
PLoS One ; 7(12): e52709, 2012.
Article de Anglais | MEDLINE | ID: mdl-23285164

RÉSUMÉ

In 2011, a novel strain of O104:H4 Escherichia coli caused a serious outbreak of foodborne hemolytic uremic syndrome and bloody diarrhea in Germany. Antibiotics were of questionable use and 54 deaths occurred. Candidate therapeutic bacteriophages that efficiently lyse the E. coli O104:H4 outbreak strain could be selected rather easily from a phage bank or isolated from the environment. It is argued that phage therapy should be more considered as a potential armament against the growing threat of (resistant) bacterial infections.


Sujet(s)
Bactériophages/génétique , Escherichia coli producteur de Shiga-toxine/virologie , Bactériolyse , Bactériophages/isolement et purification , Bactériophages/ultrastructure , Épidémies de maladies , Infections à Escherichia coli/épidémiologie , Allemagne/épidémiologie , Syndrome hémolytique et urémique/épidémiologie , Humains , Cadres ouverts de lecture , Escherichia coli producteur de Shiga-toxine/classification
6.
Emerg Infect Dis ; 15(5): 727-34, 2009 May.
Article de Anglais | MEDLINE | ID: mdl-19402958

RÉSUMÉ

Because the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) differs among the 3 countries forming the Euregio Meuse-Rhin (EMR) region (Belgium, Germany, and the Netherlands), cross-border healthcare requires information about the spread of MRSA in the EMR. We investigated the emergence, dissemination, and diversity of MRSA clones in the EMR by using several typing methods. MRSA associated with clonal complexes 5, 8, 30, and 45 was disseminated throughout the EMR. Dutch isolates, mainly associated with sequence types (ST) ST5-MRSA-II, ST5-MRSA-IV, ST8-MRSA-IV, and ST45-MSRA-IV had a more diverse genetic background than the isolates from Belgium and Germany, associated with ST45-MRSA-IV and ST5-MRSA-II, respectively. MRSA associated with pigs (ST398-MRSA-IV/V) was found in the Dutch area of the EMR. Five percent of the MRSA isolates harbored Panton-Valentine leukocidin and were classified as community-associated MRSA associated with ST1, 8, 30, 80, and 89.


Sujet(s)
Infections communautaires/transmission , Staphylococcus aureus résistant à la méticilline , Infections à staphylocoques/transmission , Antibactériens/pharmacologie , Protéines bactériennes/génétique , Belgique/épidémiologie , Clonage moléculaire , Infections communautaires/épidémiologie , Infections communautaires/microbiologie , Infection croisée/épidémiologie , Infection croisée/microbiologie , Infection croisée/transmission , Résistance bactérienne aux médicaments , Allemagne/épidémiologie , Humains , Staphylococcus aureus résistant à la méticilline/classification , Staphylococcus aureus résistant à la méticilline/effets des médicaments et des substances chimiques , Staphylococcus aureus résistant à la méticilline/génétique , Staphylococcus aureus résistant à la méticilline/isolement et purification , Tests de sensibilité microbienne , Pays-Bas/épidémiologie , Réaction de polymérisation en chaîne , Prévalence , Infections à staphylocoques/épidémiologie , Infections à staphylocoques/microbiologie , Facteurs de virulence/génétique
7.
Antimicrob Agents Chemother ; 49(10): 4263-71, 2005 Oct.
Article de Anglais | MEDLINE | ID: mdl-16189107

RÉSUMÉ

The Euregio Meuse-Rhine (EMR) is formed by the border regions of Belgium, Germany, and The Netherlands. Cross-border health care requires infection control measures, in particular since the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) differs among the three countries. To investigate the dissemination of MRSA in the EMR, 152 MRSA isolates were characterized by pulsed-field gel electrophoresis (PFGE), SCCmec typing, and multilocus sequence typing. PFGE revealed major clonal groups A, G, L, and Q, suggesting dissemination of MRSA in the EMR. Group A harbored mainly SCCmec type III and sequence types (STs) 239 and 241. The majority of the strains from group G harbored SCCmec type I and ST8 and ST247, whereas most strains from group L carried either SCCmec type IV or type I. Within group L, ST8 and ST228 were found, belonging to clonal complexes 8 and 5, respectively. Most strains from group Q included SCCmec type II and were sequence typed as ST225. Both ST225-MRSA-II and ST241-MRSA-III were novel findings in Germany. In addition, the SCCmec type of two isolates has not been described previously. One strain was classified as SCCmec type III but harbored the pls gene and the dcs region. Another strain was characterized as SCCmec type IV but lacked the dcs region. In addition, one isolate harbored both SCCmec type V and Panton-Valentine leukocidin. Finally, the SCCmec type of the strains was found to be correlated with the antibiotic susceptibility pattern.


Sujet(s)
Résistance à la méticilline , Infections à staphylocoques/épidémiologie , Infections à staphylocoques/microbiologie , Staphylococcus aureus/classification , Staphylococcus aureus/génétique , Belgique/épidémiologie , Infection croisée , Électrophorèse en champ pulsé , Allemagne/épidémiologie , Épidémiologie moléculaire , Pays-Bas/épidémiologie , Réaction de polymérisation en chaîne , Prévalence , Analyse de séquence d'ADN , Sérotypie , Staphylococcus aureus/effets des médicaments et des substances chimiques
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...